RNA Q3 2022 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+14.7% YoY

Gross Profit

-$35M-1403.5% margin

Operating Income

-$45M-1810.2% margin

Net Income

-$44M-1756.6% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+14.0%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$431M

Total Liabilities

$54M

Stockholders' Equity

$377M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+14.7%
Gross Profit	-$35M	-$23M	-53.7%
Operating Income	-$45M	-$29M	-53.4%
Net Income	-$44M	-$29M	-48.9%